Shopping Cart 0
Cart Subtotal
USD 0

Pharma Mar SA (PHM)-Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Pharma Mar SA (PHM)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company's marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar's developmental pipeline includes Aplidin (plitidepsin) for multiple myeloma and T-cell lymphoma; PM1183 (lurbinectedin) for ovarian cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.

Pharma Mar SA Key Recent Developments

Apr 27,2017: PharmaMar Demonstrates Its Progress in R&D in New York

Apr 27,2017: PharmaMar Group reports EUR45.5 million in revenues (+8%)

Mar 29,2017: The success of sarcoma treatment, seen by prestigious international oncologists

Feb 24,2017: PharmaMar continues to execute commercially in 2016, adds new partner for pipeline asset, and sees pipeline progress

Oct 27,2016: PharmaMar Group Reports 9M 2016 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

Pharma Mar SA-Key Facts 5

Pharma Mar SA-Key Employees 6

Pharma Mar SA-Key Employee Biographies 7

Pharma Mar SA-Major Products and Services 8

Pharma Mar SA-Pharmaceutical Pipeline Products Data 9

Pharma Mar SA, Pipeline Products by Therapy Area 9

Pharma Mar SA, Pipeline Products by Development Phase 10

Pharma Mar SA-History 11

Pharma Mar SA-Locations And Subsidiaries 13

Head Office 13

Other Locations & Subsidiaries 13

Section 2-Company Analysis 15

Pharma Mar SA-Business Description 15

Pharma Mar SA-Corporate Strategy 16

Pharma Mar SA-SWOT Analysis 17

SWOT Analysis-Overview 17

Pharma Mar SA-Strengths 17

Pharma Mar SA-Weaknesses 18

Pharma Mar SA-Opportunities 19

Pharma Mar SA-Threats 20

Pharma Mar SA-Key Competitors 21

Section 3-Company Financial Ratios 22

Financial Ratios-Capital Market Ratios 22

Financial Ratios-Annual Ratios 23

Performance Chart 26

Financial Performance 26

Financial Ratios-Interim Ratios 27

Financial Ratios-Ratio Charts 28

Section 4-Company's Lifesciences Financial Deals and Alliances 29

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30

Pharma Mar SA, Recent Deals Summary 31

Section 5-Company's Recent Developments 32

Apr 27, 2017: PharmaMar Demonstrates Its Progress in R&D in New York 32

Apr 27, 2017: PharmaMar Group reports EUR45.5 million in revenues (+8%) 33

Mar 29, 2017: The success of sarcoma treatment, seen by prestigious international oncologists 34

Feb 24, 2017: PharmaMar continues to execute commercially in 2016, adds new partner for pipeline asset, and sees pipeline progress 36

Oct 27, 2016: PharmaMar Group Reports 9M 2016 Financial Results 38

Jul 26, 2016: Pharma Mar Group Reports 1H 2016 Financial Results 39

Apr 28, 2016: PharmaMar Group Reports Q1 2016 Financial Results 40

Section 6-Appendix 41

Methodology 41

Ratio Definitions 41

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Pharma Mar SA, Pipeline Products by Therapy Area 9

Pharma Mar SA, Pipeline Products by Development Phase 10

Pharma Mar SA, Performance Chart (2012-2016) 26

Pharma Mar SA, Ratio Charts 28

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 30


List Of Table

List of Tables

Pharma Mar SA, Key Facts 5

Pharma Mar SA, Key Employees 6

Pharma Mar SA, Key Employee Biographies 7

Pharma Mar SA, Major Products and Services 8

Pharma Mar SA, Number of Pipeline Products by Therapy Area 9

Pharma Mar SA, Number of Pipeline Products by Development Stage 10

Pharma Mar SA, History 11

Pharma Mar SA, Subsidiaries 13

Pharma Mar SA, Key Competitors 21

Pharma Mar SA, Ratios based on current share price 22

Pharma Mar SA, Annual Ratios 23

Pharma Mar SA, Annual Ratios (Cont...1) 24

Pharma Mar SA, Annual Ratios (Cont...2) 25

Pharma Mar SA, Interim Ratios 27

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30

Pharma Mar SA, Recent Deals Summary 31

Currency Codes 41

Capital Market Ratios 41

Equity Ratios 42

Profitability Ratios 42

Cost Ratios 43

Liquidity Ratios 43

Leverage Ratios 44

Efficiency Ratios 44

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Traslational Cancer Drugs Pharma SL, Oryzon Genomics SA, GP Pharm SA, CTI BioPharma Corp, Ariad Pharmaceuticals (Spain) SL, Ability Pharmaceuticals SL